Plasma-derived complement inhibitor
C1-esterase inhibitor
Brand names: Berinert, Cinryze
Adult dose
Dose: HAE acute: 20 units/kg IV; Prophylaxis: 1000 units IV q3–4 days
Route: IV
Frequency: PRN attack / scheduled prophylaxis
Clinical pearls
- Hereditary angioedema (HAE) — acute attacks (laryngeal/abdominal) and short-term prophylaxis
- UK PIN / WAOI / HAEi: specialist immunology centres
- Patient self-administration training; alternative: lanadelumab, icatibant
Contraindications
- Hypersensitivity
Side effects
- Hypersensitivity / anaphylaxis
- Thrombosis (high-dose, prolonged)
- Headache
- Nausea
- Injection-site reactions
- Theoretical viral transmission (plasma-derived)
Interactions
- No clinically significant interactions
Monitoring
- Attack frequency / severity
- Hypersensitivity
- Thrombotic complications
Reference: BNF; UK PIN HAE guidance; WAO HAE guideline; SmPC; https://bnf.nice.org.uk/drugs/c1-esterase-inhibitor/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Lymphadenopathy Workup · NICE NG12; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023